EGFR and prostate carcinoma: Notably, IGFBP2 is an established oncogene in various tumors including myeloid leukemia, gliomas, breast, and prostate cancer, and orchestrates multiple cancer signaling pathways such as PI3K-AKT, NF-κB, and EGFR/STAT3 [31–33].